Rakuten Medical announces promising interim results from photoimmunotherapy study at ASCO 2024
Rakuten Medical, Inc., a pioneer in biotechnology focusing on precision, cell-targeting photoimmunotherapy, unveiled updated interim results from its Phase 1b/2 study of ASP-1929 photoimmunotherapy in ... Read More
Avacta Group reports promising early results for Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leading life sciences company dedicated to developing innovative oncology drugs and powerful diagnostics, has announced a crucial milestone in ... Read More